ABSI vs RLAY
ABSI and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABSIABSCI CORP | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | $1.36B | $4.16B |
| P/S | 487.3x | 270.9x |
| Revenue growth (YoY) | -38.2% | 53.4% |
| Earnings growth (YoY) | -11.7% | 18.1% |
| EBIT margin | -4297.0% | -1971.6% |
| ROE | -46.8% | -31.1% |
| ROIC | -84.6% | — |
| 1y total return | +202.9% | +368.1% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: ABSI frente a RLAY
| Métrica | ABSI | RLAY |
|---|---|---|
| Valor final | $3.7K | $5.5K |
| Retorno total | -63.2% | -44.6% |
| CAGR | -17.6% | -10.8% |
| Volatilidad | 97.7% | 77.7% |
| Sharpe | 0.24 | 0.18 |
| Sortino | 0.36 | 0.28 |
| Caída máxima | -96.2% | -94.7% |
Basado en 1293 días de negociación comunes, 2021-07-22 → 2026-09-15 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)